Literature DB >> 22727906

Diindolilmethane (DIM) selectively inhibits cancer stem cells.

Alexandre Semov1, Ludmila Iourtchenco, Lin Fang Liu, Shengmin Li, Yan Xu, Xiaoxue Su, Ekaterina Muyjnek, Vsevolod Kiselev, Valery Alakhov.   

Abstract

Epidemiologic studies repeatedly have shown chemopreventive effects of cruciferous vegetables. Indole-3-carbinol (I3C) and its metabolite diindolylmethane (DIM) were identified in these plants as active ingredients and theirs anti-tumor activities were confirmed in multiple in vitro and in vivo experiments. Here, we demonstrate that DIM is a selective and potent inhibitor of cancer stem cells (CSCs). In several cancer cell lines, DIM inhibited tumor sphere formation at the concentrations 30-300 times lower than concentrations required for growth inhibition of parental cells cultured as adherent culture. We also found that treatment with DIM overcomes chemoresistance of CSCs to cytotoxics, such as paclitaxel, doxorubicin, and SN-38. Pre-treatment of tumor spheres with DIM before implantation to mice significantly retarded the growth of primary tumors compared to tumors formed by untreated tumor spheres. The concentrations of DIM required to suppress CSCs formation are in the close range to those achievable in human plasma after oral dosing of the compound. Therefore, DIM can potentially be used in cancer patients, either alone, or in combinations with existing drugs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727906     DOI: 10.1016/j.bbrc.2012.06.062

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity.

Authors:  Apurva R Patel; Ravi Doddapaneni; Terrick Andey; Heather Wilson; Stephen Safe; Mandip Singh
Journal:  J Control Release       Date:  2015-06-14       Impact factor: 9.776

2.  Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane's efficacy and safety in the treatment of CIN: implications for cervical cancer prevention.

Authors:  Levon Ashrafian; Gennady Sukhikh; Vsevolod Kiselev; Mikhail Paltsev; Vadim Drukh; Igor Kuznetsov; Ekaterina Muyzhnek; Inna Apolikhina; Evgeniya Andrianova
Journal:  EPMA J       Date:  2015-12-21       Impact factor: 6.543

Review 3.  New Treatments in Renal Cancer: The AhR Ligands.

Authors:  Boris Itkin; Alastair Breen; Lyudmila Turyanska; Eduardo Omar Sandes; Tracey D Bradshaw; Andrea Irene Loaiza-Perez
Journal:  Int J Mol Sci       Date:  2020-05-18       Impact factor: 5.923

4.  A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.

Authors:  Vsevolod I Kiselev; Levon A Ashrafyan; Ekaterina L Muyzhnek; Evgeniya V Gerfanova; Irina B Antonova; Olga I Aleshikova; Fazlul H Sarkar
Journal:  BMC Cancer       Date:  2018-09-20       Impact factor: 4.430

5.  Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN).

Authors:  Mikhail Paltsev; Vsevolod Kiselev; Ekaterina Muyzhnek; Vadim Drukh; Igor Kuznetsov; Olga Pchelintseva
Journal:  EPMA J       Date:  2014-10-08       Impact factor: 6.543

6.  Comparative preclinical pharmacokinetics study of 3,3'-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon?

Authors:  Mikhail Paltsev; Vsevolod Kiselev; Ekaterina Muyzhnek; Vadim Drukh; Igor Kuznetsov; Olga Pchelintseva
Journal:  EPMA J       Date:  2013-12-10       Impact factor: 6.543

7.  First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN).

Authors:  Mikhail Paltsev; Vsevolod Kiselev; Vadim Drukh; Ekaterina Muyzhnek; Igor Kuznetsov; Evgeniya Andrianova; Pavel Baranovskiy
Journal:  EPMA J       Date:  2016-04-02       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.